Randomized, triple-blind, phase 2 trial (NCT02620072) evaluating oral insulin to prevent T1D progression in stage 1, high-risk children aged 2-12 years. The study will assess prevention of dysglycemia or diabetes, as measured by oral glucose tolerance test. Participants are followed for at least 24 months (55). Here, INS is linked to diabetes mellitus.